Rifaximin Size:Solid 10 mg steady-state volume of distribution

steady-state volume of distribution

IC50<10 nM vs

PubMed PMID: 16983112

Targeted Inhibition of Mutant IDH2 in Leukemia Cells Induces Cellular Differentiation

54(9):3641-50

Rifaximin Size:Solid 10 mg steady-state volume of distributionRifaximin is a semisynthetic antibiotic based on rifamycin. It has poor oral bioavailability, meaning that very little of the drug will be absorbed into the blood stream when it is taken orally. Rifaximin is used in the treatment of traveler's diarrhea, irritable bowel syndrome, and hepatic encephalopathy, for which it received orphan drug status from the U. S. Food and Drug Administration in 1998. Rifaximin interferes with transcription by binding to